Business Wire

VanEck Taps Moody’s Analytics Data for Two New ETFs

Share

Moody’s Analytics today announced that it is working with VanEck, a global investment manager, as a data and analytics provider for two new exchange-traded funds (ETFs). The funds are VanEck Vectors® Moody’s Analytics® IG Corporate Bond ETF (MIG®), whichfocuses on the US corporate investment-grade market, and the VanEck Vectors® Moody’s Analytics® BBB Corporate Bond ETF (MBBB®), which concentrates on the market’s BBB segment, for bonds with the lowest investment grade rating.

Moody’s Analytics has offered its credit risk metrics for use in the indices underlying these two new VanEck funds. VanEck is using several data points produced by the Moody’s Analytics industry-leading CreditEdgeTM solution as inputs for the indices underlying the new ETFs.

These metrics are based on information from financial markets and are combined with a detailed picture of a company's capital structure. They are used by investors for credit quality assessment and to identify corporate securities that offer attractive spreads relative to their market-implied credit risk.

In recent years, the ETF industry has grown in popularity as investors look for new smart beta fixed-income strategies. Many ETFs performed well during the financial crisis of 2007-08 and are performing strongly now, even amid the economic downturn caused by the COVID-19 pandemic.

“The CreditEdge solution has a comprehensive set of credit risk metrics for early warning detection of credit deterioration,” said Nihil Patel, Managing Director at Moody’s Analytics. “These metrics have been shown to help identify undervalued corporate securities. We are pleased that VanEck will be using these metrics as key inputs for the indices underlying their new ETFs.”

“The new corporate bond funds are designed to provide investors with robust new tools to enhance their investment-grade bond exposures,” said Fran Rodilosso, Head of Fixed Income ETF Portfolio Management at VanEck. “They offer investors income potential and outperformance without having to assume excessive risk—particularly important in this prolonged low-yield environment.”

About Moody’s Analytics

Moody’s Analytics provides financial intelligence and analytical tools to help business leaders make better, faster decisions. Our deep risk expertise, expansive information resources, and innovative application of technology help our clients confidently navigate an evolving marketplace. We are known for our industry-leading and award-winning solutions, made up of research, data, software, and professional services, assembled to deliver a seamless customer experience. We create confidence in thousands of organizations worldwide, with our commitment to excellence, open mindset approach, and focus on meeting customer needs. For more information about Moody’s Analytics, visit our website or connect with us on Twitter and LinkedIn.

Moody's Analytics, Inc. is a subsidiary of Moody's Corporation (NYSE: MCO). Moody's Corporation reported revenue of $4.8 billion in 2019, employs approximately 11,400 people worldwide and maintains a presence in more than 40 countries.

About Van Eck

VanEck has a history of looking beyond the financial markets to identify trends that are likely to create impactful investment opportunities. As of October 31, 2020, VanEck managed approximately $60.1 billion in assets, including mutual funds, ETFs and institutional accounts. It is one of the first U.S. asset managers to offer investors access to international markets. This set the tone for the firm’s drive to identify asset classes and trends—including gold investing in 1968, emerging markets in 1993, and Exchange Traded Funds in 2006—that subsequently shaped the investment management industry.

Today, VanEck offers active and passive strategies with compelling exposures supported by well-designed investment processes. The firm’s capabilities range from core investment opportunities to more specialized exposures to enhance portfolio diversification. Its actively managed strategies are fuelled by in-depth, bottom-up research and security selection from portfolio managers with direct experience in the sectors and regions in which they invest. Investability, liquidity, diversity, and transparency are key to the experienced decision-making around market and index selection underlying VanEck’s passive strategies.

Since its founding in 1955, putting clients’ interests first, in all market environments, has been at the heart of the firm’s mission.

Contact information

TRACY A. FINE
Moody’s Analytics Communications
+1.415.874.6013
Moody’s Analytics Media Relations

moodysanalytics.com
twitter.com/moodysanalytics
linkedin.com/company/moodysanalytics

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Nottinghamshire County Council Renews Support Agreement With Rimini Street for Its Mission-Critical SAP Applications21.1.2021 15:00:00 CETPress release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that Nottinghamshire County Council (NCC) has renewed its agreement with Rimini Street for Support of its SAP ECC 6.0 and SAP Business Objects software. NCC first switched to Rimini Street in 2017, achieving substantial savings in maintenance fees over the last three years, as well as related savings in avoided upgrades, process efficiencies and customization support, included at no additional charge. At a time of significant strain on public sector budgets, NCC renewed its agreement with Rimini Street to continue to achieve these essential savings as the local authority seeks to drive efficiencies in its back-office IT systems. Additionally, NCC has the reassurance that their software systems will be supported for a guaranteed minimum of 15 years from the time they swi

Alvarez & Marsal Announces 2021 Managing Director Promotions21.1.2021 15:00:00 CETPress release

Leading global professional services firm Alvarez & Marsal (A&M) has announced the promotion of 37 professionals from across Benelux, Brazil, Germany, India, Italy, Sweden, the United Kingdom and the United States to the position of Managing Director. John Suckow, A&M’s Chief Operating Officer, stated, “For over 37 years, A&M professionals have delivered leadership, action and results to our clients. In this unique and challenging year, our leaders have not wavered, and we have achieved extraordinary professional growth and success. We congratulate all of our newly promoted Managing Directors and applaud their commitment to A&M's core values of integrity, quality, objectivity, fun, personal reward and inclusive diversity.” Brazil Henrique Biscolla, São Paulo Eduardo Gallardo, São Paulo Emerson Santana, São Paulo Corporate Performance Improvement Tres Evans, Dallas Michael Nelson, Chicago Kristin Shelley, Dallas Global Disputes and Investigations Nikki Coles, London Europe - Performance

XClinical to Merge with Carenity and Fortress Medical Systems Forming a New Data Science Company Serving Life Science Markets Worldwide21.1.2021 14:00:00 CETPress release

XClinical, a leading vendor of eClinical software has announced a merger with France-based Carenity, a social platform supporting patients and caregivers worldwide, and Fortress Medical Systems, the US-based vendor of Clindex®, an integrated CTMS and EDC system. All three companies are long-established, leading providers in their respective markets. The group is financed by German Private Equity firm BID Equity. Together, the three businesses will form a new, innovative data science company, powered by cutting edge technology. The group brings best in class data science and eClinical software solutions together, delivering end-to-end coverage of the clinical development process for their 150+ customers in over 20 countries, including US, Germany, France, UK, Italy, Japan and China. Biopharma, Medical Device as well as Academic sponsors and CROs worldwide will benefit from progressive and cost-efficient solutions such as feasibility studies, Real World Evidence data collection, patient

HempFusion Announces Large-Scale Distribution Agreement with Fullscript.com to Launch Doctor Practitioner Sales Channel21.1.2021 13:01:00 CETPress release

HempFusion Wellness Inc. (TSX:CBD.U) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that it has entered into a large-scale distribution agreement with Fullscript.com (“Fullscript”), a leading eCommerce platform that allows health professionals to dispense professional-grade natural health products. Fullscript is one of the largest distributors in the category, providing nutritional supplements to over 80,000 practitioners and over 600,000 patients across the United States and Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210121005282/en/ Total Care Daily Probiotic from Biome Research (Photo: Business Wire) This agreement signifies HempFusion’s strategic launch into the doctor practitioner sales channel. HempFusion’s seven Biome Research SKUs will be available to ship from Fullscript distribution centers starting Febr

Tinubu® Square Announces Technological Collaboration With Microsoft21.1.2021 13:00:00 CETPress release

Tinubu Square, the market leader for enterprise software solutions to Credit and Surety Insurers, announces cooperation with Microsoft, the leading provider in Business Intelligence solutions. Olivier Placca, Tinubu Square co-founder and Deputy CEO declares: “This cooperation is strategic for Tinubu Square to continue to offer carriers best-in-class technologies in the long run using the strength of Power BI across all business lines of our SaaS-based, end-to-end Enterprise Solution Platform. Our primary objective is answering our customers’ needs. Integrating Power BI to our Credit Insurance and Surety Platform offers them key benefits such as powerful insights, a scalable solution and settings on-the-fly. To take full advantage of our Business Intelligence capabilities, customers can tailor their own reports using a specifically designed Tinubu® CIS data model, increasing efficiency and data relevance. Offer Sadey, Chief Technical Officer at Tinubu Square, explains: “Before choosing

numares and Bruker Sign Agreement to Enable Advanced Metabolomics-based Clinical Diagnostics21.1.2021 12:00:00 CETPress release

Leading metabolomics based diagnostics company numares AG and analytical instrumentation and solution provider Bruker Corporation have signed an agreement to collaborate to bring new diagnostics tests utilizing NMR to the laboratory market for unmet medical needs. The tests are based on the automated measurement of metabolites using a strong magnet field, and artificial intelligence. The platform is marketed under the numares brand AXINON®. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210121005438/en/ numare's AI-driven, NMR-based diagnostic platform AXINON is easy to operate by laboratory technicians. (Photo: Business Wire) Based on a longstanding collaboration between the two companies, the agreement creates a combination of numares’ expertise in leveraging metabolomics for software-based diagnostics with world-leading nuclear magnetic resonance (NMR) technology from Bruker. This leads to more rapid, accurate and persona

AriBio Co., Ltd. Announces Last Patient Last Visit in Phase 2 Clinical Trial of AR1001 in Mild to Moderate Alzheimer’s Patients21.1.2021 11:14:00 CETPress release

AriBio Co., Ltd., a clinical-stage biopharmaceutical company based in South Korea, announced today, 21st of January 2021, the completion of last patient last visit in a Phase 2 study of AR1001. AR1001 is a first-in-class, orally dosed investigational drug for mild to moderate Alzheimer’s disease. A total of 210 patients were enrolled, and 171 (81.4%) subjects completed 6-month dosing in the study. “We are pleased to report the achievement of this critical milestone, and AriBio is looking forward to announcing the topline results by the end of Q1’2021. Despite the challenges presented by the COVID-19 pandemic, we were able to complete dosing and follow-up assessments in this trial. We are extremely grateful to our study participants, their family members and healthcare professionals who worked tirelessly to complete the primary assessments of the study,” said James Rock, Senior Vice President of Clinical Operations. AriBio offered an optional 6-month extension phase of the study, where

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom